652.00p-12.00 (-1.81%)10 Mar 2025, 16:35
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo

International Biotechnology Trust PLC Shares News & Articles

From an employee share scheme at Rolls Royce to the Dogs of the FTSE – how Paul approaches the financial markets

Paul's very first taste of investing came when his employer, aerospace and defence company Rolls Royce (RR.), introduced an employee share scheme which gave him what seemed to be a low-risk way of getting exposure to its shares.It seemed low risk, explains Paul, because the scheme allowed employees to save a monthly or four weekly amount for five years and at the end of the period the savings and

Weight loss 2.0: What next for the companies at the forefront of fighting global obesity

Investor excitement surrounding weight-loss drugs has arguably been as great if not greater than that seen for everything AI (artificial intelligence) in the last two years.Market leaders Novo Nordisk (NOVO-B:CPH) and Eli Lilly (LLY:NYSE), makers of Wegovy and Zepbound respectively, have seen their share prices soar as investors seemingly extrapolate their initial success years into the future.Ben

Meta spending plans irk investors while Tesla rally sends Nasdaq higher | Wall Street Week

After last week?s market spasm over hints from Fed officials that rates may need to rise rather than fall due to the resilience of the US economy, this week the focus moved on to earnings with around one third of S&P 500 companies posting first-quarter updates.So far most firms have beaten estimates, leading to slim gains for the indices, but an increasing number have tempered their guidance for t

Clarity over new manager gives International Biotechnology Trust a welcome boost

International Biotechnology Trust (IBT) 650pGain to date: 4.8%We said to buy shares in International Biotechnology Trust (IBT) on 1 June 2022 at 620.1p as there was an opportunity to buy cheaply into a sector that had been heavily sold off.Biotech can be a high-risk place to invest and so using an investment trust or fund is often a better way to get exposure as the risks are spread across a portf

RTW Biotech Opportunities has a great track record which isn’t reflected in a wide discount to net asset value

Since inception in October 2019 RTW Biotech Opportunities (RTW) has delivered 65.3% growth in NAV (net asset value), smashing the performance of the Russell 2000 Biotech index which is down 0.7% as well as the NBI (Nasdaq Biotech Index) which is up 20.6% over the same period.Despite the superior performance to the benchmark and peers, the shares trade at an unwarranted 23% discount to NAV, represe

Biotech companies in demand as pharmaceutical companies spend billions on takeovers

With so much macroeconomic uncertainty, the recent mergers and acquisitions spree has lost momentum apart from one sector.Big pharmaceutical firms are awash with cash, yet patent cliffs (expiration of patent protection) present challenges which can be partially fixed by buying smaller biotech firms with products almost ready to go to market.International Biotechnology Trust's (IBT) Ailsa Craig and

International Biotechnology Trust manager gives notice to focus on core venture business

- Investment manager wants to terminate contract- Current fund managers to stay on for smooth transition- Likely to be strong interest from other fund managersBiotechnology specialist International Biotechnology Trust (IBT) said investment adviser SV Health Investors had given notice to terminate the management of the trust from 9 February 2024 or earlier if agreed by the parties.SV Health Investo
Showing 1 to 20 of 36